文献速递免疫规划传染病防控与疫情报告

既往COVID-19感染与BNT162b2/Pfizer疫苗第一剂后不良事件增加相关,但第二剂后不相关

Prior COVID-19 infection is associated with increased Adverse Events (AEs) after the first, but not the second, dose of the BNT162b2/Pfizer vaccine.
PubMed 文献 · Vaccine · 2021-12-04

该研究对英格兰东北部1238名医护人员进行问卷调查,32%自报既往SARS-CoV-2 PCR和/或抗体检测阳性。既往COVID-19者第一剂后不良事件更严重,但第二剂后无此差异;第二剂不良事件频率/严重度更高且更倾向全身性,女性和年轻医护人员更易报告不良事件,给药间隔无影响。

要点

  • 既往COVID-19者第一剂后不良事件更严重,第二剂后无差异。
  • 第二剂不良事件频率/严重度更高,更倾向全身性,与COVID-19史无关。
  • 女性和年轻医护人员两剂后均更易报告不良事件。

核心结论

  • 既往COVID-19与第一剂BNT162b2/Pfizer疫苗后不良事件增加相关,但与第二剂后不良事件无关。
  • 第二剂不良事件频率/严重度更高且更倾向全身性,与COVID-19史无关;女性和年轻医护人员更易报告不良事件;给药间隔对不良事件无影响。
  • 持续症状性COVID-19与第二剂后不良事件频率/严重度更高相关,但与第一剂后无关。
  • 总体不良事件为自限性和短暂性(即<48小时)。

研究设计与样本

  • 基于问卷调查的研究,纳入英格兰东北部1238名医护人员(HCWs)。
  • 32%自报既往SARS-CoV-2 PCR和/或抗体检测阳性。

主要发现

  • 既往COVID-19者第一剂后不良事件更严重,但第二剂后无此差异。
  • 第二剂不良事件频率/严重度更高,与COVID-19史无关,且更倾向全身性。
  • 女性和年轻医护人员两剂后均更易报告不良事件;给药间隔对不良事件无影响。
  • 持续症状性COVID-19与第二剂后不良事件频率/严重度更高相关,但与第一剂后无关。
  • 总体不良事件为自限性和短暂性(即<48小时)。

临床怎么用

  • 这些发现对疫苗犹豫和推荐给药方案的指南制定有启示。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The BNT162b2/Pfizer SARS-CoV-2 vaccine has been widely used in the UK, particularly amongst healthcare workers (HCWs). To establish whether previous COVID-19 influenced vaccine-associated Adverse Events (AEs), we conducted a survey-based study of HCWs in Northeast England. Out of 1238 HCWs, 32% self-reported prior positive PCR and/or antibody test for SARS-CoV-2. Post-dose AEs were worse in those with prior COVID-19 after the first, but not the second dose of vaccine. Second dose AEs were greater in frequency/severity, regardless of COVID-19 history, and they were more systemic in nature. Women and younger HCW were more likely to report AEs after both doses, while dosing interval had no effect on AEs. Ongoing Symptomatic COVID-19 was associated with greater frequency/severity of AEs after dose 2, but not dose one. Overall, AEs were self-limiting and short-lived (i.e.,<48 h) in nature. These findings have implications for vaccine hesitancy and informing guidelines for recommended dosing protocols.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Raw RK, Rees J, Kelly CA, et al. Prior COVID-19 infection is associated with increased Adverse Events (AEs) after the first, but not the second, dose of the BNT162b2/Pfizer vaccine. Vaccine. 2021. PMID: 34895935. doi:10.1016/j.vaccine.2021.11.090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。